Company Overview
Company Type: Public Company
Company Status: Acquired
Website: -
Number of Employees: 65
Ticker: -
Year Founded: 1996


Business Description
As of December 11, 2006, GFR Pharmaceuticals Inc. was acquired by New Century Scientific Investment Ltd. in a reverse merger transaction. GFR Pharmaceuticals, Inc. engages in formulating, blending, encapsulating, and packing of nutritional products. The company manufactures 300 products in capsule, tablet, powder, and liquid form. It produces vitamin and mineral formulations, indication and herbal formulas, nutritional herbal formulas for men and women, sports nutrition products, family fitness products, weight loss and diet products, soy and whey protein shakes, green food powders, daily nutrient packets, and over the counter pharmaceutical products. GFR Pharmaceuticals Inc. distributes its products on a private label basis through health food retail stores, mass market retail through department and grocery stores, mail order, health practitioners, and the Internet. The company was formerly known as Laredo Investment Corp. and changed its name in August, 2004. GFR Pharmaceuticals Inc. was incorporated in 1996 and is based in Maple Ridge, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
9.8
Market Capitalization
1.2
EBITDA
0.4
EBIT
0.3
P/Diluted EPS Before Extra
12.9x
Net Income
0.1
Total Debt
2.1
Price/Tang BV
0.6x
Capital Expenditure
(0.1)
Total Assets
5.7
Total Debt/EBITDA
4.9x


Currency in CAD in mm, LTM as of Sep-30-2006 TEV and Market Cap are calculated using a close price as of Dec-11-2006

Key Professionals
No Key Professionals have been profiled.


Primary Industry Classification
Personal Care Products


Primary Office Location
201A Street Suite11405 | Maple Ridge, BC | V2X 0Y3 | Canada
Phone: 604-460-8440   

Parent Company
GFR Pharmaceuticals Inc.


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Laredo Investment Corporation
Laredo Investment Corporation was acquired by GFR Pharma Ltd. in a reverse merger transaction on 04/04/2000. Previously, Laredo Investment Corp. was in the development stage that did not have any significant operations. The company was organized to seek, investigate, and acquire an interest in one or more business opportunities.

United States and Canada
Asset Management and Custody Banks
-
-
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-3-2006
Dec-11-2006
Merger/Acquisition
Target
GFR Pharmaceuticals Inc.
GFR Pharmaceuticals Inc.

-
May-10-2006
Cancelled
Merger/Acquisition
Target
GFR Pharmaceuticals Inc.
Vita Vir Pty Ltd

-
Aug-31-2005
Cancelled
Merger/Acquisition
Target
GFR Pharmaceuticals Inc.
HYB Holding Corp.

-
Aug-23-2000
Jul-12-2000
Merger/Acquisition
Buyer
Web Search Technologies Inc.
Laredo Investment Corp. (nka:GFR Pharmaceuticals Inc.)

11.88
Jan-21-2000
Apr-4-2000
Merger/Acquisition
Buyer
Laredo Investment Corporation
Laredo Investment Corp. (nka:GFR Pharmaceuticals Inc.)

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jan-18-2007
Auditor Changes
GFR Pharmaceuticals Inc. Announces Change of Auditors
Dec-12-2006
Executive/Board Changes - Other, Announcements of Earnings, Executive Changes - CFO
GFR Pharmaceuticals Inc. Announces Earnings Results for the Five Months Period Ended May 31, 2006 ; Announces Executive Changes
Dec-11-2006
M&A Transaction Closings
New Century Scientific Investment Ltd. completed the acquisition of GFR Pharmaceuticals Inc. in a reverse merger transaction.
Sep-29-2006
Executive/Board Changes - Other
GFR Pharmaceuticals Inc. Announces Director Changes
Aug-25-2006
Ticker Changes
GFR Pharmaceuticals Inc. will Change its Ticker to GFRP from GFRP.E


Advisors
Most Recent Auditor
Robison Hill & Co.


Most Recent Auditor
Robison, Hill & Co


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Apr-13-2007
Dec-31-2006
GFR Pharmaceuticals Inc.
SEC
10KSB
836 KB
Nov-01-2006
Sep-30-2006
GFR Pharmaceuticals Inc.
SEC
10QSB
368 KB
Oct-17-2006
Oct-17-2006
GFR Pharmaceuticals Inc.
SEC
DEF 14C
173 KB
Oct-02-2006
Oct-02-2006
GFR Pharmaceuticals Inc.
SEC
PRE 14C
173 KB
Sep-29-2006
Sep-28-2006
GFR Pharmaceuticals Inc.
SEC
8-K (5.02, 7.01, 9.01)
29 KB
Aug-23-2006
Jun-30-2006
GFR Pharmaceuticals Inc.
SEC
10QSB
59 KB
Aug-14-2006
Jun-30-2006
GFR Pharmaceuticals Inc.
SEC
NT 10-Q
6 KB
Jul-03-2006
Jun-30-2006
GFR Pharmaceuticals Inc.
SEC
8-K (1.01, 7.01, 9.01)
679 KB
Jun-06-2006
Jun-05-2006
GFR Pharmaceuticals Inc.
SEC
8-K (1.02, 7.01, 9.01)
26 KB
May-17-2006
Mar-31-2006
GFR Pharmaceuticals Inc.
SEC
10QSB
59 KB

Key Executives and Professionals Details
No Key Executives and Professionals exist.

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
